Protein translation is inhibited by the unfolded protein response (UPR)-induced eIF-2α phosphorylation to protect against endoplasmic reticulum (ER) stress. In addition, we found additional inhibition of protein translation owing to diminished mTORC1 (mammalian target of rapamycin complex1) activity in ER-stressed multiple myeloma (MM) cells. However, c-myc protein levels and myc translation was maintained. To ascertain how c-myc was maintained, we studied myc IRES (internal ribosome entry site) function, which does not require mTORC1 activity. Myc IRES activity was upregulated in MM cells during ER stress induced by thapsigargin, tunicamycin or the myeloma therapeutic bortezomib. IRES activity was dependent on upstream MAPK (mitogenactivated protein kinase) and MNK1 (MAPK-interacting serine/threonine kinase 1) signaling. A screen identified hnRNP A1 (A1) and RPS25 as IRES-binding trans-acting factors required for ER stress-activated activity. A1 associated with RPS25 during ER stress and this was prevented by an MNK inhibitor. In a proof of principle, we identified a compound that prevented binding of A1 to the myc IRES and specifically inhibited myc IRES activity in MM cells. This compound, when used alone, was not cytotoxic nor did it inhibit myc translation or protein expression. However, when combined with ER stress inducers, especially bortezomib, a remarkable synergistic cytotoxicity ensued with associated inhibition of myc translation and expression. These results underscore the potential for targeting A1-mediated myc IRES activity in MM cells during ER stress.
INTRODUCTION
Regulation of protein translation is important in multiple myeloma (MM) because a high rate of immunoglbulin (Ig) production places the malignant cell at risk for endoplasmic reticulum (ER) stressinduced death. In addition to efficient proteasome function, expanded ER membrane development and a heightened unfolded protein response (UPR) mechanism, 1,2 MM cells also protect against ER stress by repressing generalized TORC1 activity to limit unnecessary protein translation. For example, MM cells transcriptionally upregulate ARK5 and DEPTOR, 3, 4 two proteins that suppress TORC1 4, 5 function and global cap-dependent translation. However, to maintain tumor cell viability during ER stress, translation of key proteins must continue. Our prior work 6, 7 suggested the possibility that this translation can occur through cap-independent, IRES (internal ribosome entry site)-dependent mechanisms. IRES-dependent translation does not require mTOR (mammalian target of rapamycin) activity (that is, no risk of enhanced global translation) and is independent of mRNA cap binding to the eIF-4F initiation complex. It is mediated by direct binding of an IRES sequence in the mRNA's 5′-untranslated region (UTR) to the ribosome, facilitated by RNA-binding proteins termed ITAFs (IRES-trans-acting factors).
A protein that needs to be continuously expressed for MM cell proliferation and survival is c-myc. C-myc expression is a key factor in MM progression 8 and MM cells appear to be addicted to c-myc expression. 9 The c-myc RNA contains a well-characterized IRES 10 and we have previously reported 6, 7 on myc IRES function in MM cells responding to interleukin-6 or mTOR inhibitors.
In keeping with the key regulatory role of protein translation, we have found a rapid inhibition of mTORC1 (mammalian target of rapamycin complex1) function occurring in ER stress in MM cells (see Results, below) . This effect, in addition to the negative effect of UPR-induced eIF-2α phosphorylation, 2 should prevent capdependent translation and leave IRES activity as the only fail-safe mechanism for protein translation. We, thus, investigated whether myc IRES function is an important determinant of maintained myc expression and MM cell fate during ER stress. Our results confirm this hypothesis and suggest that IRES function could be a promising therapeutic target. Indeed, we also demonstrate the therapeutic potential of a selective inhibitor of myc IRES function during enhanced ER stress in MM cells.
RESULTS

ER stress inhibits mTORC1 function in MM cells
Initial experiments investigated the effects of ER stress on mTORC1. The 8226, MM1.S and OPM-2 MM lines were exposed to tunicamycin (TU), thapsigargin (TH) or clinically relevant concentrations of bortezomib (2-10 nM) for 7 h followed by immunoblot assay. P70 and 4EBP-1 are substrates of mTORC1 and S6 is a substrate of p70. As shown in Figures 1a-f , exposure of all three lines to all three drugs resulted in depressed mTORC1 function identified by diminished phosphorylation of p70 and S6. At this early time point (7 h), there was no effect of any of the ER stress inducers on percent viability or viable cell recovery. Additional immunoblots (not shown) confirmed the generation of ER stress, demonstrated by enhanced phosphorylation of IRE-1 and induction of CHOP (C/EBPb homologous protein) expression. Experiments in ANBL-6 MM cells (Supplementary Figure 1) show similar effects on p70 and S6 phosphorylation. ER stress inducers also downregulated 4EBP-1 phosphorylation. In 8226, tunicamycin/thapsigargintreated MM1.S and bortezomib-treated OPM-2 cells, this was shown with use of a phosphospecific antibody (Supplementary Figure 2A) . In bortezomib-treated MM1.S and tunicamycin/ thapsigargin-treated OPM-2 cells, use of an antibody detecting total 4EBP-1 identified three bands representing differential phosphorylation of 4EBP-1. The γ-hyperphosphorylated band predominates in control cells and, following exposure to ER inducers, the hypophosphorylated α band predominates (Supplementary Figure 2A) .
We also studied four separate CD138-selected 1°MM samples. A 6 h exposure of these 1°cells to tunicamycin (at 25 μM) or thapsigargin (1 μM) also demonstrated inhibited phosphorylation of p70 (Figure 1g ). There was no detected cell cytotoxicity at this early time (data not shown).
The inhibition of mTORC1 should result in depressed capdependent translation. Assays for lambda Ig expression in 8226 MM cells support this contention. As shown (Figure 1h ), ER stress inducers decreased Ig expression by 40-50%. In contrast, c-myc protein expression in all three lines was not decreased by ER stress and the accompanying mTORC inhibition (Figures 1a-f) . In some of these immunoblots, there are more than one distinct myc protein bands detected. This is due to the fact that there are two separate species expressed from either the P1 or P2 promoters (generating p67 or p64 proteins). 11 Both these proteins contain exon 3 and could be detected by our anti-myc antibody, which is specific for a peptide fragment of exon 3. Additional isoforms of myc are also produced by alternative splicing (Bodescot and Brison, 12 see below Figure 6 ). The intermittent detection of these additional myc protein species can be a function of the duration of gel electrophoresis. Although Figure 1d suggests a slight decrease in myc expression followingexposure of MM1.S cells to the lowest concentration of bortezomib (2 nM), when we quantified c-myc expression by densitometric analysis of all myc bands between p64 and p67 in four separate experiments, it is clear that, although markedly inhibiting TORC1 activity (p70 phosphorylation), bortezomib had no inhibitory effect on c-myc expression at all concentrations (Supplementary Figure 2B) . The finding of an actual increase in c-myc protein expression in In addition to the cell line experiments, reprobing three of the four primary samples also demonstrated no inhibition of c-myc protein expression during ER stress (Figure 1g ). Collectively, these results confirm that enhanced ER stress induction in MM cells causes rapid depression of mTORC1 but c-myc protein expression is maintained.
Myc IRES activity is stimulated during ER stress We first tested if increases in steady-state myc RNA could explain maintained myc protein levels during ER stress. On the contrary, in 8226 cells challenged with bortezomib or tunicamycin for 7 h, instead of an increase there was a moderate decrease in myc RNA levels (Figure 2a) . Results in MM1.S cells were similar (Supplementary Figure 3A) , without any increases in steady-state myc RNA. This suggests that effects on RNA expression do not have a role in the maintenance of c-myc protein levels during ER stress. However, a caveat to this interpretation is that an earlier myc RNA induction may have occurred (see Discussion). As bortezomib, by preventing proteasome degradation of myc, 13 could theoretically inhibit degradation, we also tested c-myc protein stability in bortezomib-treated MM cells ( Figure 2b ). As shown, there was an actual decrease in myc protein stability with a T1/2 of 20 min versus T1/2 of 460 min in control untreated cells. A similar decrease in T1/2 in MM1.S cells was seen (Supplementary Figure 3B) . Thus, increases in protein stability could not explain maintained myc protein levels during bortezomib exposure. To assess specifically myc translational efficiency, we performed a polysome analysis. This assay is based on the observation that well-translated transcripts are associated with polysomes and poorly translated mRNAs are monosomal. Thus, MM cells were treated, polysomes were separated from monosomes on sucrose gradients and associated RNAs were quantified by quantitative PCR (qt-PCR). Figure 2c demonstrates an increase in myc translation (white bars) in bortezomib-and tunicamycin-treated cells (that is, increase in polysome-associated RNA). In contrast, translation of actin is modestly, but significantly (P o0.05) suppressed (black bars), further supporting the notion that cap-dependent translation is inhibited by the associated mTORC1 depression. Bortezomib and tunicamycin likewise increased myc translation in MM1.S cells (Supplementary Figure 3C) .
The remarkable increase in myc translation during a time when mTORC1 is inhibited was noteworthy and strongly suggested a stimulation of IRES-dependent translation. To investigate this, we performed IRES-dependent reporter assays. MM cells were transfected with either pRF or PRmF dicistronic reporter constructs as shown in Figure 2d and treated with tunicamycin, thapsigargin or bortezomib. The c-myc 5′-UTR, containing its IRES, was subcloned into the intracistronic space between the Renilla and Firefly (FF) luciferase open reading frames in the pRF vector to yield the pRmF vector. The pRmF reporter's FF luciferase translation is driven by the myc 5′-UTR and is a reflection of IRES-dependent, cap-independent translation, whereas Renilla expression is due to cap-dependent, IRES-independent translation. Similarly, constructed control reporters, where the p27 5′-UTR or Cricket paralysis virus IRES (pCPV) were subcloned into the intracistronic space (not shown), were also generated. Reporter expression results are normalized for transfection efficiency by cotransfection with a β-galactosidase construct. Preliminary experiments had revealed that β-gal expression was unaffected by tunicamycin, thapsigargin or bortezomib in short-term exposures (Supplementary Figure 4) . Figure 2e demonstrates FF expression caused by the myc 5′-UTR in untreated 8226 cells was 10-fold increased versus pRFtransfected cells without any effects on Renilla expression. When exposed to bortezomib, the increase in FF expression because of the myc 5′-UTR was now 45-fold increased. It is difficult to see in Figure 2e , but bortezomib induced a corresponding decrease (~40%) in pRmF Renilla expression, attesting to the suppression of cap-dependent translation in bortezomib-treated cells. Control experiments (Figure 2e ) in the same cells demonstrated no significant effect of bortezomib on p27 IRES (pRp27F) or pCPV activity. Although the pCPV activity was only 1.7-fold increased over its pRF control, this activity was ablated in a reporter vector containing an inactive mutated CPV IRES 11 (data not shown). Notably, bortezomib did not enhance this IRES activity. Figure 2f demonstrates similar stimulatory effects of thapsigargin or tunicamycin on myc IRES activity. In the absence of ER stress inducers, the presence of the myc 5′-UTR in the intracistronic space in these experiments increased FF luciferase (black bars) to 7-fold versus that of the pRF control vector without effects on Renilla expression. For thapsigargin, the increase in FF expression because of the myc 5′-UTR was now 10, 18 and 22-fold versus that of the pRF vector in cells treated with 0.25, 0.5 and 1 μM, respectively. Likewise, while exposure to tunicamycin at 3.2 μM only minimally enhanced FF expression (8.5-fold increase versus that of the pRF vector), 6.4 μM stimulated FF expression to 18-fold versus similarly treated pRF-transfected cells. Both thapsigargin and tunicamycin induced decreases in Renilla expression in a manner similar to bortezomib-treated cells. In addition, control experiments with pCPV ( Figure 2e) show no stimulatory effect of tunicamycin on pCPV activity. Thus, the stimulation of myc IRES activity following exposure to these agents is relatively specific. This stimulation likely allows for maintained c-myc protein expression during TORC1 inhibition and depressed capdependent translation following induction of ER stress.
We had previously demonstrated a role for the MNK1 (MAPKinteracting serine/threonine kinase 1) kinase in rapamycinstimulated myc IRES activity. 7 In addition, both ERK and p38MAPK (mitogen-activated protein kinase) pathways have been previously implicated in myc IRES function. 14, 15 As both ERK and p38 can phosphorylate and activate MNK1, we hypothesized that MAPK pathways, working downstream via MNK1 stimulation, were important for ER stress-induced myc IRES activity. To test initially a role for MNK1, 8226 or MM1.S MM cells were exposed to increasing concentrations of tunicamycin or thaspigargin for 7 h followed by immunoblot assay for phosphorylated MNK1. As shown in Figure 3a , MNK1 becomes phosphorylated in both MM lines. A similar induction of MNK phosphorylation induced by thapsigargin was identified in two 1°MM samples (Figure 3b) . To test the significance of MNK activation, we first used CGP57380, an MNK inhibitor.
7 Figure 3c demonstrates the efficacy of CGP used at 50 μM in its ability to inhibit thapsigargin-induced MNK kinase activity, the latter assayed by immunoblot for phosphorylation of eIF-4E, a well known MNK1 substrate. This concentration of CGP was then used in the IRES-dependent reporter assay (Figure 3d ). IRES activity is reported as a ratio of FF (F)/Renilla (R) luciferase expression with comparison to the pRF reporter plasmid, which is arbitrarily set as '1'. As shown, the myc 5′-UTR in pRmF increases the F/R ratio to 6-fold over the pRF vector and the addition of thapsigargin, at either 1 or 0.5 μM, significantly enhances IRES activity to 14-and 10-fold, respectively. However, the exposure to CGP prevents the thapsigargin-induced IRES stimulation. Similar results were obtained in thapsigargin-and tunicamycin-treated MM1.S cells coincubated with CGP (Supplementary Figure 5) . Confirmatory experiments used short hairpin RNA (shRNA) to silence either MNK1 or MNK2 in 8226 cells (Figure 3e ). Cells were infected with shRNA targeting a scrambled sequence (SCR) or two separate MNK1 or MNK2 sequences (Cl 1 or Cl 2). The infected cells were tested for myc IRES activity stimulated by tunicamycin or thapsigargin ( Figure 3f ). As shown, MNK1 knockdown significantly inhibited the ER stress-induced IRES stimulation, while MNK2 knockdown had little effect.
Next, to assess MAPK pathway stimulation, we performed immunoblot assay for ERK or hsp-27 phosphorylation. The latter was chosen as an indicator for p38MAPK activity. As shown in Figure 4a , exposure of 8226 cells to tunicamycin (12.5 μM) or thapsigargin at 0.5 or 1 μM induced both hsp-27 and ERK phosphorylation at 7 h. We then tested a role for MAPK pathways by using inhibitors of ERK (PD98059, 50 μM) or p38 (SB202190, 10 μM). Figure 4b demonstrates the specificity of the inhibitors and also compares them with the CGP MNK inhibitor concentration used in Figure 3 . In this experiment, thapsigargin (0.5 μM) clearly stimulated ERK and MNK1 phosphorylation and, more modestly, hsp-27 phosphorylation. The CGP MNK inhibitor, which reduces MNK activity but not MNK phosphorylation, additionally had no effect on ERK or hsp-27 phosphorylation attesting to its specificity for MNK activity. Its stimulatory effect on MNK1 phosphorylation may be due to negative feedback loops responding to inhibited MNK kinase activity. The ERK PD98059 inhibitor significantly inhibited ERK phosphorylation but not hsp-27 phosphorylation and the p38 SB202190 inhibitor specifically inhibited hsp-27 phosphorylation but not ERK phosphorylation. As expected, both MAPK inhibitors individually inhibited downstream MNK phosphorylation. The same concentrations of ERK PD98059 and p38 SB202190 inhibitors were then used in the IRES reporter assay and compared with the CGP MNK inhibitor. As shown (Figure 4c) , each of the three inhibitors was capable of decreasing thapsigargininduced myc IRES activity stimulated by either 1 or 0.5 μM thapsigargin. To confirm the importance of the MAPK pathways, we also silenced ERK1, ERK2 or p38 by shRNA (Figures 4d and e) . Although these MAPK pathways are critical for long-term MM cell survival, viability and cell recovery was unaffected for up to 96 h after lentiviral infection. The shRNA targeting ERK1 was specific for ERK1 silencing, although the shRNA targeting ERK2 also demonstrated some off-target silencing of ERK1 as well as ERK2 (Figure 4d ). As p38 expression was quite low in SCR-infected control MM cells, we tested hsp-27 phosphorylation as a read-out for p38 expression/activity and, as shown in Figure 4e , p38 shRNA significantly abated hsp-27 phosphorylation. The shRNA-infected MM cells were then studied in IRES-dependent reporter assays. As shown in Figure 4f , silencing of either ERK1, ERK2 or p38 resulted in a significant inhibition of ER stress-induced IRES activity. In cells concurrently silenced with ERK1+ERK2 or with all three shRNA targeting MAPK pathways, the inhibition of IRES activity was even more impressive.
Trans-acting factors mediating stimulated IRES activity To further identify factors involved in the IRES response to ER stress, we performed a screen based on a recent publication 16 where proteins can be identified, which interact with RNA or assemble into larger RNA-protein complexes within mammalian cells. The screen depends upon transcriptional activation of the HIV LTR and its GFP signal when an interaction between the HIV TAT protein and TAR RNA element at the 5′ end of nascent transcripts enhances elongation (Supplementary Figure 6) . In the 'TAT-hybrid' screen, the TAR is replaced by the c-myc IRES RNA and a TAT-fusion library is generated from ER-stressed 8226 MM cells (thapsigargin, 1 μM for 7 h). The MM cell library was cloned into the TAT-fusion plasmid. This TAT-fusion RNA library was then transfected into a U87 reporter cell line, which stably expresses the HIV-LTR-myc-IRES-GFP reporter. Proteins that bind the c-myc IRES will transcriptionally activate GFP expression. Positive clones with activated GFP expression are sorted by fluorescenceactivated cell sorting and DNA obtained for sequencing. The screen can detect RNA-protein interactions in the context of mammalian cells (that is, advantages over yeast screening) where important mammalian accessory factors or posttranslational modifying enzymes are available to assemble proper complexes.
A strongly positive hit was hnRNP A1, a known myc ITAF. 6 We also identified a non-essential 40 S ribosomal subunit protein RPS25 as a dominant clone isolated from the library screens. To confirm identification of these two IRES-binding proteins, we performed RNA pull-down experiments. The 8226 myeloma cell extracts were incubated with biotinylated myc IRES RNA in the sense or antisense orientation. Immunoblot was then performed on the proteins precipitated by these RNAs. We also hypothesized that, as a direct component of the 40 S ribosomal subunit, RPS25 was unlikely to interact directly with the c-myc IRES and was a positive 'hit' in the screens as a result of an indirect interaction mediated by hnRNP A1. Thus, the RNA pull-down assay was also performed in 8226 cells where hnRNP A1 was silenced by shRNA. Figure 5a demonstrates that the myc IRES in the sense orientation was capable of precipitating both hnRNP A1 and RPS25 in control 8226 cells (empty vector-transfected). Actin was not nonspecifically precipitated by the IRES. In contrast, neither protein was precipitated by myc IRES RNA in the antisense orientation. In hnRNP A1-knocked out 8226 cells, the myc IRES precipitated considerably less RPS25, indicating that the IRES-RPS25 interaction was hnRNP A1-dependent.
We next silenced either A1 or RPS25 in 8226 cells to test their roles in IRES activity. Figure 5b demonstrates successful shRNA knockdown using two separate target sequences for both proteins. The shRNA-silenced cells had normal viability (490%) Similarly, knockdown of hnRNP A1 (bottom) prevented the IRES response to both thapsigargin and tunicamycin. Infection with sh2 was considerably more inhibitory, consistent with its greater ability to silence A1 expression (Figure 5b ). A1 knockdown had no effect on p27 IRES activity (Figure 5d ), indicating selectivity for the A1-dependent myc IRES. Thus, the TAT-hybrid screen identified two proteins, hnRNP A1 and RPS25, which interacted with the myc IRES and were integral for an myc IRES response to ER stress.
To assess whether A1 and RPS25 associated, we performed coimmunoprecipitation experiments in 8226 cells. As shown in Figure 5e , A1 associated with RPS25 when MM cells were challenged with tunicamycin, thapsigargin or bortezomib. Furthermore, inhibitors of ERK (PD), p38 (SB) or MNK (CGP) diminish the binding reaction (Figure 5f ).
Identification of an myc IRES inhibitor
We designed a high-throughput yeast three-hybrid screen (Supplementary Figure 7) to identify inhibitors of the A1-IRES interaction and interrogated the NCI/DTP inhibitor library of 145 000 compounds. Our screen identified a class of compounds, which inhibits A1 binding to the myc IRES with compound '11' as a potential lead compound (Figure 6a ). We first confirmed the ability of compound 11 to inhibit A1/IRES binding in the RNA pull-down assay. As shown in Figure 6b , a marked decrease in binding between A1 and the IRES was identified when compound 11 was present. Compound 11 also prevents MM cell myc IRES activity in 8226 cells, but had no effect on control p27 IRES activity (Figure 6c ). Additional IRESes that are unaffected by compound 11 are BAG-1, XIAP and p53 (Supplementary Figure 8) . In addition, compound 11 also prevents myc IRES activity following challenge with ER stress inducers such as thapsigargin and bortezomib ( Figure 6d ). As a negative control, there was no effect on stimulated myc IRES activity resulting from exposure to a similarly sized known inhibitor of the hepC IRES, benzimidazole-2.
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As expected, compound 11 also had no significant effect on myc translation when used alone (Figure 6e ) as cap-dependent translation would be unaffected. As shown previously (Figure 2) , bortezomib, used alone, significantly stimulates myc translation. However, when bortezomib is combined with compound 11, a significant inhibition of myc translation occurs (Figure 6e ). This is associated with similar effects on protein expression analyzed by immunoblot ( Figure 6f ). As shown, tunicamycin, bortezomib or compound 11 (inhibitor (Inh)) have little inhibitory effect on myc protein expression when used alone. However, myc expression is Figure 3F , mean ± s.d., n = 3. *Significantly lower activity relative to SCR control cells, P o0.05.
C-myc IRES activity in multiple myeloma Y Shi et al significantly inhibited when compound 11 is combined with either tunicamycin or bortezomib. The associated ER-stress-induced TORC1 inhibition is again shown as downregulated 4E-BP1 phosphorylation. Compound 11 had no significant effects on myc steady-state RNA levels (Supplementary Figure 9) .
Synergistic anti-MM cytotoxicity
To first assess a therapeutic strategy targeting A1-mediated IRES function during ER stress, we tested sensitivity to bortezomib in A1-silenced MM cells. As shown in Figure 7a , loss of A1 resulted in a sensitization to bortezomib. These data suggested that compound 11 could be synergistic with ER stress inducers. When used alone, compound 11 had minimal cytotoxicity or apoptosis against 8226 and MM1.S cells (Figures 7b-d) . However, adding these subtoxic concentrations to thapsigargin (Figure 7b ) or bortezomib ( Figure 7c ) in 8226 cells significantly increased cytotoxicity. Similarly, synergistic apoptosis resulted (% apoptosis is the number above the bars). Median effect/combinatorial index (CI) analysis confirmed synergy for all combinations. Remarkably low CI values are shown below the figures for cytotoxicity and apoptosis. These CI data are plotted against fraction affected in Supplementary Figure 10 . In more limited experiments in terms of concentrations used, studies in MM1.S cells (Figure 7d ) also demonstrated a marked interaction of the two therapeutics. Little effect of compound 11 or thapsigargin used alone was seen while the combination markedly inhibited growth and induced apoptosis (left panels). Similar results were seen in MM1.S cells challenged with compound 11 ± bortezomib (right panels).
In addition, three 1°specimens also demonstrated a synergistic interaction between compound 11 and bortezomib ( Figure 7E ). Although the patient samples were variably sensitive to bortezomib alone (sample no. 2 was sensitive to 5 nM), all three samples demonstrated enhanced cytotoxicity when non-toxic concentrations of compound 11 (500 or 1000 nM) were combined with bortezomib.
DISCUSSION
Restraint of mTORC1 and cap-dependent translation is one mechanism by which MM cells deal with the enhanced basal ER stress they must face. Indeed, loss-of-function alleles of mTOR confer susceptibility to plasmacytoma generation in mice. 18 When further challenged with ER stress, our results (Figure 1 ) indicate an additional rapid downregulation of mTORC1. Cap-dependent translation was depressed, shown by decrease in Ig expression, a decrease in actin translation (Figure 2c ) and decrease in Renilla expression in reporter assays. It is remarkable that, with such depressed mTORC1 function, induced eIF-2α phosphorylation 2 and inhibited cap-dependent translation, myc translation is actually increased and protein expression is maintained, signifying the importance of myc IRES function.
Although our assays for steady-state myc RNA (Figure 2a ) did not demonstrate any increases induced by tunicamycin or bortezomib, these assays were performed after 7 h. Previous work 19, 20 demonstrated that thapsigargin and tunicamycin could induce an immediate-early c-myc RNA response in MEF cells. This was somewhat dependent on PERK activation in the UPR. 19 It is, thus, possible that a PERK-dependent early myc RNA induction has a role in the increased myc protein expression seen in the tunicamycin/thapsigargin-stimulated 8226 cells where the RNA induction had resolved by 7 h. There may also be cell-specific differences in the activation of PERK accounting for the selectivity of the myc increases in 8226 cells. However, this possibility does not detract from the importance of stimulated IRES activity to maintain myc translation during ER stress. We have reported previously 21 that an MNK-dependent phosphorylation of eIF-4E could maintain translation of selective viability-promoting mRNAs in MM cells without causing dangerous elevations in global translation. However, c-myc translation was not supported in this manner. 17 The current study demonstrates an additional MNK-dependent response, namely stimulation of IRES activity, which is critical for continued myc translation and viability during ER stress. As such, the study also identifies the myc IRES as an especially promising therapeutic target in MM and, as a proof of principle, demonstrates the efficacy of a specific IRES inhibitor when used in combination with ER stress inducers. If non-malignant host cells are not as impacted by ER stress and retain normal cap-dependent translation, they would not be adversely affected by an IRES inhibitor and a 'therapeutic window' would exist.
Prior work also supports ERK/p38MAPK pathways and IRES stimulation as protective responses to ER stress. [22] [23] [24] Our work identifies MNK1 activity as the probable link between upstream MAPK pathway activation and IRES upregulation. The stimulation of hnRNP A1/RPS25 binding during ER stress and its prevention by an MNK inhibitor suggest the following model: ER stress stimulates MNK activity subsequent to upstream MAPK activation. The A1 ITAF binds the myc IRES in the nucleus and accompanies it to the cytoplasm. At that site, MNK phosphorylates A1 and/or the ribosomal protein RPS25, resulting in enhanced A1/RPS25 binding. Via the A1/RPS25 interaction, ribosomal loading to the myc IRES is facilitated leading to IRES-dependent translation. In support of this hypothesis is the finding that MNK-1-induced phosphorylation of A1 has been reported. 25 Furthermore, our preliminary data indicate that recombinant MNK1 can also phosphorylate RPS25 (not shown).
In addition to ER stress, dysregulated myc itself may render MM cells sensitive to an IRES inhibitor. Myc-driven tumorigenesis requires a heightened UPR and autophagic response to deal with ER stress owing to increased protein expression, 26 and the myc transcriptional program accomplishes this. Similarly, the transcriptional program includes elements of the IRES machinery such as RPS25. 27 An additional myc IRES ITAF, YB-1, is also transcriptionally induced by myc in MM cells. 28 These data underscore a positive feedback loop in MM where dysregulated myc transcriptionally induces the IRES machinery, including the myc ITAFs hnRNP A1 and YB-1, which, in turn, are critical for translation of myc. Thus, there is additional scientific rationale for targeting myc IRES function in myc-driven tumors.
It remains to be seen whether constitutive MM cell ER stress in patients is sufficient to render the malignant clone susceptible to an IRES inhibitor or whether additional ER stress must be induced. If additional stress is required, the future promise of such drugs would be in combination with bortezomib as we have shown. However, other combinations are possible as well. For example, as myc IRES function is a mode of resistance to mTOR inhibitors, 29 combined use of the myc IRES inhibitor with an mTOR inhibitor may be efficacious. In addition, combining an IRES inhibitor to prevent myc translation with a bromodomain inhibitor 30, 31 to prevent myc transcription might allow a more profound ablation of myc expression with only moderate doses of each drug necessary so as to avoid serious side effects.
MATERIALS AND METHODS
Cell lines, reagents and plasmids
The MM cell lines were obtained from ATCC (Manassas, VA, USA). The pRF reporter construct was a kind gift from Dr A Willis (University of Leicester, Leicester, UK). The myc IRES was cloned into pRF as described 6 to obtain pRmF. The Cricket paralysis virus empty vector, wild-type and mutated IRES dicistronic reporter plasmids were gifts from Dr Eric Jan (University of British Columbia, Vancouver, BC, Canada) and as described previously. 32 The plKO vectors targeting A1 and RPS25 were purchased from Life Technologies (Grand Island, NY, USA). Lentiviral infection of MM cells was performed as described. 7 CGP57380, PD98059 and SB202190 were purchased from Calbiochem (Temecula, CA, USA) and EMD Millipore (Temecula, CA, USA).
Primary MM cells
Primary MM cells were obtained and purified as described. 6, 7 Evaluation of translation, proteinturnover and RNA Polysome analysis was performed as described. 6 Briefly, after separation of extracts on a 15-50% sucrose gradient, fractions were collected and UV absorbance at 254 nm measured to generate a polysome profile to differentiate monosome and polysome fractions. Associated myc RNA was quantified by qt-PCR. C-myc protein turnover assays were performed as described. 6 Qt-PCR for myc RNA and GAPDH (glyceraldehyde 3-phosphate dehydrogenase) RNA was performed as described. 6 Myc IRES activity Reporter constructs were transfected into lines using Effectene Transfection Reagent (Qiagen, Valencia, CA, USA). Transfection efficiency was generally 5-10%. After 18 h, cells were treated and then harvested, followed by detection of luciferase activities as described. 6 All luciferase activity is normalized to the luciferase values obtained for pRF in the absence of treatment.
RNA pull-down assay
This assay was performed as described. 33 Briefly, the biotinylated c-myc 5′-UTR was generated as described. 33 Cell extract (200 μg) was mixed with 12.5 pmol of biotinylated probe in binding buffer for 15 min at 30°C and added to 400 μl streptavidin magnetic particles (Promega, Sunnyvale, CA, USA) for 10 min at room temperature to allow binding. After dissociation of RNA from bound proteins, the latter were identified by immunoblot. 
